Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 4Unknown 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gastrointestinal 1Breast 1

Conditions

Breast Neoplasms 1

Interventions

Cyclophosphamide 89Capecitabine 88Trastuzumab 81Docetaxel 81Paclitaxel 65Epirubicin 57pyrotinib 55Tamoxifen 54Letrozole 53Fulvestrant 49Vinorelbine 43Carboplatin 43Doxorubicin 41Radiotherapy 33Anastrozole 32exemestane 31Neoadjuvant Therapy 29palbociclib 27Drug Therapy 27Fluorouracil 24Bevacizumab 24pertuzumab 23Cisplatin 23eribulin 22Exercise 21130-nm albumin-bound paclitaxel 21Goserelin 20Gemcitabine 20Chemotherapy, Adjuvant 19Albumin-Bound Paclitaxel 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Palonosetron × Breast × Clear all
NCT03606369 2018-07-30

Effectiveness and Quality of Life Analysis of Palonosetron Against Ondansetron Combined With Dexamethasone and Fosaprepitant in Prevention of Acute and Delayed Emesis Associated to Chemotherapy Moderate and Highly Emetogenic in Breast Cancer.

Instituto Nacional de Cancerologia de Mexico

Phase 2/3 Unknown
560 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡